Medical Devices Divestitures in 2026

Laborie Medical Technologies has completed the acquisition of the JADA® System and the team behind it from Organon in a transaction announced in late January 2026. The deal — part of Organon’s divestiture program (previously disclosed as up to $465 million) — brings more than 90 employees and an FDA-cleared device for rapid control of postpartum hemorrhage into Laborie’s obstetrics portfolio to expand the company’s maternal health capabilities.

BioStem Technologies (OTC: BSEM) has acquired the surgical and wound care business of BioTissue Holdings, Inc. for approximately $15 million upfront, with up to $25 million of contingent milestone and royalty payments. The deal includes the Neox and Clarix product lines, a nationwide commercial sales organization and assigned GPO contracts, expanding BioStem's access into hospital inpatient and outpatient wound-care markets and adding assets that generated roughly $29 million in 2025.